Abstract
The aim of this retrospective study was to investigate the safety and efficacy of Oxcarbazepine (OXC) in monotherapy in patients with brain tumour and epilepsy. We studied 21 patients; in 8 patients OXC was the first therapeutic choice, in 13 it substituted the first therapy. Oxcarbazepine induced no side effects. OXC induced a complete seizures control in 14 patients, a seizures rate reduction higher than 50% in 4 patients, an unmodified seizures rate in 2 patients. These preliminary data seem to indicate that OXC treatment in patients with brain tumours is quite safe and effective.
Translated title of the contribution | Efficacy and tolerability of Oxcarbazepine in brain tumours and epilepsy |
---|---|
Original language | Italian |
Pages (from-to) | 261-262 |
Number of pages | 2 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 133-134 |
Publication status | Published - Jul 2006 |
ASJC Scopus subject areas
- Clinical Neurology